Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Thorsten Vetter

Showing results (11-20 of 19) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 19 results.
The Journal of Biological Chemistry|July 27, 2010
Formation of a ternary complex among NHERF1, beta-arrestin, and parathyroid hormone receptorChristoph Klenk, Thorsten Vetter, Alexander Zürn, et al.
Trials|October 4, 2014
Adaptive clinical trial designs for European marketing authorization: a survey of scientific advice letters from the European Medicines AgencyAmelie Elsäßer, Jan Regnstrom, Thorsten Vetter, et al.
British Journal of Clinical Pharmacology|September 12, 2023
Patient-reported, observer-reported and performance outcomes in qualification procedures at the European Medicines Agency 2013-2018Marcio Silva, Jane Moseley, Thorsten Vetter, et al.
Drug Discovery Today|October 28, 2017
Marketing authorisation of orphan medicines in Europe from 2000 to 2013Matthias P Hofer, Hanna Hedman, Maria Mavris, et al.
Clinical Pharmacology and Therapeutics|February 9, 2022
Biomarker Qualification at the European Medicines Agency: A Review of Biomarker Qualification Procedures From 2008 to 2020Elisabeth Bakker, Natalie M Hendrikse, Falk Ehmann, et al.
NPJ Digital Medicine|March 29, 2023
Evolving regulatory perspectives on digital health technologies for medicinal product developmentSeya Colloud, Thomas Metcalfe, Scott Askin, et al.
Frontiers in Pharmacology|May 24, 2021
Perspectives on a Way Forward to Implementation of Precision Medicine in Patients With Diabetic Kidney Disease; Results of a Stakeholder Consensus-Building MeetingElisabeth Bakker, Peter G M Mol, João Nabais, et al.
Clinical Pharmacology and Therapeutics|June 3, 2025
Optimizing Patient Registries for Regulatory Decision Making - Key Learnings From an HMA/EMA Multistakeholder WorkshopKelly Plueschke, Carla Jonker, Hanna Kankanen, et al.
Digital Biomarkers|May 19, 2023
Reverse Engineering of Digital Measures: Inviting Patients to the ConversationIeuan Clay, Nele Peerenboom, Dana E Connors, et al.
Pageof 2

Showing results (11-20 of 19) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 19 results.
The Journal of Biological Chemistry|July 27, 2010
Formation of a ternary complex among NHERF1, beta-arrestin, and parathyroid hormone receptorChristoph Klenk, Thorsten Vetter, Alexander Zürn, et al.
Trials|October 4, 2014
Adaptive clinical trial designs for European marketing authorization: a survey of scientific advice letters from the European Medicines AgencyAmelie Elsäßer, Jan Regnstrom, Thorsten Vetter, et al.
British Journal of Clinical Pharmacology|September 12, 2023
Patient-reported, observer-reported and performance outcomes in qualification procedures at the European Medicines Agency 2013-2018Marcio Silva, Jane Moseley, Thorsten Vetter, et al.
Drug Discovery Today|October 28, 2017
Marketing authorisation of orphan medicines in Europe from 2000 to 2013Matthias P Hofer, Hanna Hedman, Maria Mavris, et al.
Clinical Pharmacology and Therapeutics|February 9, 2022
Biomarker Qualification at the European Medicines Agency: A Review of Biomarker Qualification Procedures From 2008 to 2020Elisabeth Bakker, Natalie M Hendrikse, Falk Ehmann, et al.
NPJ Digital Medicine|March 29, 2023
Evolving regulatory perspectives on digital health technologies for medicinal product developmentSeya Colloud, Thomas Metcalfe, Scott Askin, et al.
Frontiers in Pharmacology|May 24, 2021
Perspectives on a Way Forward to Implementation of Precision Medicine in Patients With Diabetic Kidney Disease; Results of a Stakeholder Consensus-Building MeetingElisabeth Bakker, Peter G M Mol, João Nabais, et al.
Clinical Pharmacology and Therapeutics|June 3, 2025
Optimizing Patient Registries for Regulatory Decision Making - Key Learnings From an HMA/EMA Multistakeholder WorkshopKelly Plueschke, Carla Jonker, Hanna Kankanen, et al.
Digital Biomarkers|May 19, 2023
Reverse Engineering of Digital Measures: Inviting Patients to the ConversationIeuan Clay, Nele Peerenboom, Dana E Connors, et al.
Pageof 2